JP2003507342A5 - - Google Patents

Download PDF

Info

Publication number
JP2003507342A5
JP2003507342A5 JP2001516570A JP2001516570A JP2003507342A5 JP 2003507342 A5 JP2003507342 A5 JP 2003507342A5 JP 2001516570 A JP2001516570 A JP 2001516570A JP 2001516570 A JP2001516570 A JP 2001516570A JP 2003507342 A5 JP2003507342 A5 JP 2003507342A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
carbon
phenyl
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003507342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/021021 external-priority patent/WO2001012227A1/en
Publication of JP2003507342A publication Critical patent/JP2003507342A/ja
Publication of JP2003507342A5 publication Critical patent/JP2003507342A5/ja
Pending legal-status Critical Current

Links

JP2001516570A 1999-08-12 2000-08-02 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物 Pending JP2003507342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
US09/373,261 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (2)

Publication Number Publication Date
JP2003507342A JP2003507342A (ja) 2003-02-25
JP2003507342A5 true JP2003507342A5 (enExample) 2007-09-13

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001516570A Pending JP2003507342A (ja) 1999-08-12 2000-08-02 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物

Country Status (24)

Country Link
EP (1) EP1202746B1 (enExample)
JP (1) JP2003507342A (enExample)
KR (1) KR20020018201A (enExample)
CN (1) CN1229142C (enExample)
AR (1) AR029763A1 (enExample)
AT (1) ATE341341T1 (enExample)
AU (1) AU783116B2 (enExample)
BR (1) BR0013219A (enExample)
CA (1) CA2380904C (enExample)
CZ (1) CZ2002474A3 (enExample)
DE (1) DE60031127T2 (enExample)
DK (1) DK1202746T3 (enExample)
EA (1) EA006876B1 (enExample)
ES (1) ES2272305T3 (enExample)
HK (1) HK1042244A1 (enExample)
HU (1) HUP0203162A3 (enExample)
IL (1) IL147913A0 (enExample)
MX (1) MXPA02001448A (enExample)
NO (1) NO20020663L (enExample)
NZ (1) NZ517120A (enExample)
PL (1) PL353267A1 (enExample)
PT (1) PT1202746E (enExample)
WO (1) WO2001012227A1 (enExample)
ZA (1) ZA200201156B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
EP1409481B1 (en) 2001-07-16 2006-10-04 Astrazeneca AB Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1542989B1 (en) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1551824B1 (en) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
EP1758601A1 (en) 2004-06-03 2007-03-07 F.Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
RU2606114C2 (ru) * 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
EP1039910A1 (en) * 1997-11-06 2000-10-04 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Similar Documents

Publication Publication Date Title
JP2003507342A5 (enExample)
JP2008515913A5 (enExample)
RU2001131356A (ru) Замещенные 3-циано-[1.7], [1.5] и [1.8] нафтиридиновые ингибиторы тирозинкиназ
EP1202746B1 (en) Nsaid and egfr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
JP2001515071A5 (enExample)
RU2006127414A (ru) Хинолиновые промежуточные соединения ингибиторов рецептора тирозинкиназы и их синтез
CA2426461A1 (en) Nitrogen-containing aromatic derivatives
CA2299632A1 (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
RU2002117422A (ru) 4-пиримидинил-N-ацил-L-фенилаланины
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
RU2006106267A (ru) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
RU2004110725A (ru) Гетероциклические производные арилзамещенных пиридинов, использование их в качестве блокаторов натриевых каналов, фармацевтическая композиция
JP2005501796A5 (enExample)
JP2019507179A5 (enExample)
RU2003114740A (ru) Азотсодержащие ароматические производные
RU2008138649A (ru) Применение а1-агонистов аденозина и/или двойных а1/а2в-агонистов аденозина для получения лекарственных средств для лечения заболеваний
RU2004119414A (ru) 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
WO2006042100A2 (en) Method for the treatment of polycystic kidney disease
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
RU2003103780A (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
US8440675B2 (en) Potentiator of radiation therapy
JP2005503435A5 (enExample)
RU2005103618A (ru) Ингибирующие циклооксигеназу-2 (цог-2) производные пиридина
RU2001135802A (ru) Антагонисты рецептора брадикинина
EP2370079A2 (en) Hsp90 inhibitors for therapeutic treatment